Friday, July 10, 2026

pharma · Not applicable, Healthy Volunteers · advanced/metastatic non-squamous non-small cell lung cancer (NSCLC)

mAbxience

Mabxience Research SL is a pharma organization headquartered in Madrid, ES. Primary therapeutic focus areas include Not applicable, Healthy Volunteers, advanced/metastatic non-squamous non-small cell lung cancer (NSCLC),

madrid, ES HQ
2009 Founded
1,194 Employees
EMA registrant Type
Company details
Status
Public
HQ
madrid, ES
Founded
2009
Employees
1,194
Programs
5
Drugs
10
Patents
0
Clinical program

MB04-C-01-23

Phase 3 · small molecule · Rheumatoid Arthritis

MB04-C-01-23 for Rheumatoid Arthritis is a Phase 3 program (small_molecule) at Mabxience Research SL with 1 ClinicalTrials.gov record(s).

← All Mabxience Research SL projects Phase 3 small molecule active

Internal code MB04-C-01-23

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Mabxience Research SL
Phase
Phase 3
Modality
small_molecule
Indication
Rheumatoid Arthritis
Status
active
Trials
1